ENTERO HEALTHCARE SOLU L
ENTERO · General/Diversified · NSE
₹1,196
Current Market Price
Fair Value (DCF)
₹1,375
Discount to FV
+15.0%
Updated just now
YieldIQ Score
55/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
16%
ROE
6.8%
Debt/Equity
0.40
WACC
11.1%
Market Cap
₹5,203 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.7%
Return on capital employed
EV / EBITDA
30.7×
Enterprise multiple
Debt / EBITDA
3.3×
Leverage vs earnings
Interest Coverage
4.7×
EBIT covers interest
Current Ratio
2.46×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
26.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,195.8
Bear case
Discount -114.3%
Base case
Discount +13.0%
Bull case
Discount +27.5%
Ratio Trends
ENTERO · last 5 annual periods
ROE
6.8%
ROCE
11.7%
Operating Margin
—
Debt / Equity
0.40×
PE
—
EV / EBITDA
—
Historical Financials
ENTERO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2515 Cr | ₹3293 Cr | ₹3888 Cr | ₹5096 Cr | ₹6591 Cr | +27.2% |
| EBITDA | ₹26.0 Cr | ₹64.9 Cr | ₹121 Cr | ₹211 Cr | ₹277 Cr | +80.6% |
| EBIT | — | — | ₹101 Cr | — | — | +0.0% |
| PAT | ₹-29.9 Cr | ₹-11.6 Cr | ₹39.1 Cr | ₹94.8 Cr | ₹115 Cr | — |
| EPS (diluted) | — | — | ₹10.81 | — | — | +0.0% |
| CFO | ₹-35.3 Cr | ₹-45.3 Cr | ₹-36.6 Cr | ₹-76.9 Cr | ₹96.2 Cr | — |
| CapEx | ₹-9.9 Cr | ₹-5.5 Cr | ₹-5.4 Cr | ₹-11.3 Cr | ₹-67.5 Cr | — |
| FCF | ₹-45.1 Cr | ₹-50.8 Cr | ₹-42.0 Cr | ₹-88.2 Cr | ₹28.7 Cr | — |
| Total Assets | ₹1126 Cr | ₹1309 Cr | ₹2345 Cr | ₹2703 Cr | ₹3600 Cr | +33.7% |
| Total Debt | ₹355 Cr | ₹438 Cr | ₹338 Cr | ₹385 Cr | ₹677 Cr | +17.6% |
| Shareholders' Equity | ₹561 Cr | ₹595 Cr | ₹1638 Cr | ₹1724 Cr | ₹1689 Cr | +31.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ENTERO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 FDC FDC | — | — | Pending | 11.3% | 18.6× |
NEPHROPLUS NEPHROPLUS | — | — | Pending | 6.9% | — |
 SUVEN SUVEN | — | — | Pending | — | — |
SUPRIYA SUPRIYA | — | — | Pending | 18.9% | — |
 THYROCARE THYROCARE | — | — | Pending | 16.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ENTERO in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ENTERO HEALTHCARE SOLU L (ENTERO.NS) trades at 1195.80 vs a model fair value of 1375.17, a gap of 15.0%. Piotroski F-score: 5/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ENTERO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ENTERO →
Compare
Head-to-head with peers
Compare ENTERO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ENTERONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.